MedTrace Logo

A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis

NCT02295865 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2017-07-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of JNJ-38518168 in participants with moderate to severe plaque-type psoriasis (common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches).

Conditions

Interventions

DRUG

JNJ-38518168 60 mg

Two tablets of JNJ-38518168, 30 milligram (mg) each for a total of 60 mg, orally, once daily.

DRUG

JNJ-38518168 30 mg

One tablet of JNJ-38518168, 30 mg, orally, once daily.

DRUG

JNJ-38518168 3 mg

One tablet of JNJ-38518168, 3 mg, orally, once daily.

DRUG

Placebo

Matching Placebo either 30 mg tablet or 3 mg tablet will be administered orally.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-17
Primary Completion
2016-03-11
Completion
2016-03-11

Countries

  • United States
  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02295865 on ClinicalTrials.gov